NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
12 Jun 2018

Vivet Therapeutics Appoints Eduardo Bravo as New Chairman of the Board

Vivet Therapeutics today announced the appointment of Eduardo Bravo as Chairman of its Board of Directors.

10 May 2018

BioClin Therapeutics, Inc.,Completes $50 Million Series B Financing with Addition of New Investors

BioClin Therapeutics, Inc., announced today expansion of its Series B financing to $50 million to broaden its clinical development activities.
03 Apr 2018

CorWave is set to receive about €3 million in financing through France’s Worldwide Innovation Challenge for its NovaPulse program, a mini-invasive solution for cardiac support

CorWave announced today that it has been awarded almost €3 million in financing for its R&D program NovaPulse in the Silver Economy category.

16 Mar 2018

Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson’s disease

H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) today announced signing of a definitive agreement in which Lundbeck will acquire Prexton.
15 Mar 2018

OxThera announces the randomization of the first patient into its phase III EPHEX study with Oxabact

OxThera AB, announces the randomization of the first patient into its phase III study, EPHEX, with Oxabact.
09 Mar 2018

AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury

AM‐Pharma B.V., today announced positive results from its adaptive Phase II study in 301 sepsis patients with Acute Kidney Injury (AKI), the largest therapeutic study in AKI to date.
06 Mar 2018

Sanifit Announces Results of the Phase II Clinical Trial of SNF472 in Patients with Calciphylaxis

Laboratoris Sanifit S.L., announced today the completion of its Phase II clinical trial of SNF472, its lead candidate for the treatment of the orphan disease calciphylaxis, with both primary and secondary endpoints being successfully met.
05 Mar 2018

Kala Pharmaceuticals Appoints Gregory Perry to Board of Directors and as Audit Committee Chair

Kala Pharmaceuticals, Inc. today announced the appointment of Gregory Perry to the Company’s Board of Directors and Chair of its Audit Committee.
20 Feb 2018

Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain Therapeutics

Minoryx Therapeutics and Gain Therapeutics announce today the spin off of the Minoryx Site-directed Enzyme Enhancement Therapy (SEE-Tx) platform into Gain Therapeutics.
QIAGEN enters into agreement to acquire STAT-Dx, plans to launch a next-generation, fully integrated multiplex platform for syndromic disease testing<
31 Jan 2018

QIAGEN enters into agreement to acquire STAT-Dx, plans to launch a next-generation, fully integrated multiplex platform for syndromic disease testing

QIAGEN has agreed to acquire all shares of STAT-Dx for approximately $147 million in cash and additional payments of up to about $44 million.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.